Orchid Pharma Ltd Stock Price Today (NSE: ORCHPHARMA)
Fundamental Score
Orchid Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Orchid Pharma Ltd share price today is ₹482.45, down 5.52% on NSE/BSE as of 30 March 2026. Orchid Pharma Ltd (ORCHPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.35K (Cr). The 52-week high for ORCHPHARMA share price is ₹899.00 and the 52-week low is ₹489.00. At a P/E ratio of 83.18x, ORCHPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 8.21% and a debt-to-equity ratio of 0.22.
Orchid Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Orchid Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Orchid Pharma Share Price Analysis: Navigating a Shifting Pharmaceutical Landscape
The pharmaceutical industry is currently witnessing a surge in demand for complex generics and active pharmaceutical ingredients (APIs), creating opportunities for companies with strong manufacturing capabilities and strategic partnerships. This analysis examines the current financial standing of Orchid Pharma, with a specific focus on its share price. The Orchid Pharma share price currently stands at ₹680.549988, reflecting market sentiment regarding its future growth potential.
A key metric to consider is the company's Price-to-Earnings (PE) ratio of 83.18. This suggests that investors are paying a relatively high premium for each rupee of Orchid Pharma's earnings compared to the broader market. Further investigation is needed to determine if this premium is justified by anticipated future growth or represents potential overvaluation. Comparatively, examining peers like
Mankind Pharma Ltd and their management track record might provide a benchmark for Orchid Pharma's leadership effectiveness and strategic vision, which are critical drivers of long-term shareholder value.The Return on Capital Employed (ROCE) of 8.07% is a crucial indicator of how efficiently Orchid Pharma is utilizing its capital to generate profits. A higher ROCE typically signifies a stronger competitive advantage and a wider economic moat. However, at 8.07%, Orchid Pharma's ROCE suggests a moderate level of capital efficiency. Improving this metric would be essential for bolstering its long-term sustainability and differentiating itself from competitors like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd.
Ultimately, understanding the drivers behind Orchid Pharma's financial performance requires a deep dive into its financial statements, competitive landscape, and growth strategies. This brief analysis is part of a comprehensive 80-parameter fundamental audit, rigorously verified by Sweta Mishra, designed to provide a holistic view of the company's investment potential. The purpose of this document is to observe data and does not offer financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Orchid Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ORCHPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Consistent Growth Track Record (13.76% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (21.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (22.53% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹183.13 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (8.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.07%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 83.18x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-121.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-13.10%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Orchid Pharma Ltd Financial Statements
Comprehensive financial data for Orchid Pharma Ltd including income statement, balance sheet and cash flow
About ORCHPHARMA (Orchid Pharma Ltd)
Orchid Pharma Ltd is a dynamic and multifaceted pharmaceutical entity rooted in India, focused on the intricate processes of creating, refining, and distributing a comprehensive ra...nge of pharmaceutical products. The company's core competence lies in the development and manufacturing of active pharmaceutical ingredients (APIs), the very building blocks of effective medications. This expertise extends to the production of finished dosage formulations, encompassing a variety of delivery methods, and also venture into the realm of nutraceuticals, catering to the growing demand for health and wellness products. Orchid Pharma operates with a commitment to quality and precision, ensuring the efficacy and safety of its diverse product portfolio. The company's API product line is particularly robust, showcasing a broad spectrum of therapeutic categories. Orchid Pharma specializes in the production of both oral and injectable cephalosporins, crucial antibiotics used to combat a range of bacterial infections. Furthermore, their portfolio spans human and veterinary applications, demonstrating a commitment to health across species. In addition to cephalosporins, Orchid Pharma manufactures a variety of other antibiotics, including betalactams, macrolides, fluoroquinolones, and imidazoles. This demonstrates their comprehensive approach to tackling infectious diseases and supporting the healthcare needs of a diverse patient population. Orchid Pharma's impact reaches beyond the borders of India, with a significant export presence in approximately 40 countries. This global reach signifies the company's commitment to making essential pharmaceuticals accessible to a wider audience and reflects its adherence to international quality standards. By actively participating in the global pharmaceutical market, Orchid Pharma contributes to advancements in healthcare on a worldwide scale. This dedication to innovation, quality, and accessibility positions Orchid Pharma as a key player in the ever-evolving pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
ORCHPHARMA Share Price: Frequently Asked Questions
What is the current share price of Orchid Pharma Ltd (ORCHPHARMA)?
As of 30 Mar 2026, 12:03 pm IST, Orchid Pharma Ltd share price is ₹482.45. The ORCHPHARMA stock has a market capitalisation of ₹4.35K (Cr) on NSE/BSE.
Is ORCHPHARMA share price Overvalued or Undervalued?
ORCHPHARMA share price is currently trading at a P/E ratio of 83.18x, compared to the industry average of 31.77x. Based on this relative valuation, the Orchid Pharma Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ORCHPHARMA share price?
The 52-week high of ORCHPHARMA share price is ₹899.00 and the 52-week low is ₹489.00. These values are updated daily from NSE/BSE price data.
What factors affect the Orchid Pharma Ltd share price?
Key factors influencing ORCHPHARMA share price include quarterly earnings growth (Sales Growth: -13.10%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Orchid Pharma Ltd a good stock for long-term investment?
Orchid Pharma Ltd shows a 5-year Profit Growth of 22.53% and an ROE of 8.21%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.22 before investing in ORCHPHARMA shares.
How does Orchid Pharma Ltd compare with its industry peers?
Orchid Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare ORCHPHARMA share price P/E of 83.18x and ROE of 8.21% against the industry averages to determine competitive standing.
What is the P/E ratio of ORCHPHARMA and what does it mean?
ORCHPHARMA share price has a P/E ratio of 83.18x compared to the industry average of 31.77x. Investors pay ₹83 for every ₹1 of annual earnings.
How is ORCHPHARMA performing according to Bull Run's analysis?
ORCHPHARMA has a Bull Run fundamental score of 41.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ORCHPHARMA belong to?
ORCHPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Orchid Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for ORCHPHARMA?
ORCHPHARMA has an ROE of 8.21%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Orchid Pharma Ltd generates profits from shareholders capital.
How is ORCHPHARMA debt-to-equity ratio and what does it indicate?
ORCHPHARMA has a debt-to-equity ratio of 0.22, which indicates conservative financing with low financial risk.
What is ORCHPHARMA dividend yield and is it a good dividend stock?
ORCHPHARMA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Orchid Pharma Ltd shares.
How has ORCHPHARMA share price grown over the past 5 years?
ORCHPHARMA has achieved 5-year growth rates of: Sales Growth 13.76%, Profit Growth 22.53%, and EPS Growth 21.18%.
What is the promoter holding in ORCHPHARMA and why does it matter?
Promoters hold 69.84% of ORCHPHARMA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Orchid Pharma Ltd.
What is ORCHPHARMA market capitalisation category?
ORCHPHARMA has a market capitalisation of ₹4347 crores, placing it in the Small-cap category.
How volatile is ORCHPHARMA stock?
ORCHPHARMA has a beta of N/A. A beta > 1 suggests the Orchid Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ORCHPHARMA operating profit margin trend?
ORCHPHARMA has a 5-year average Operating Profit Margin (OPM) of 11.64%, indicating the company's operational efficiency.
How is ORCHPHARMA quarterly performance?
Recent quarterly performance shows Orchid Pharma Ltd YoY Sales Growth of -13.10% and YoY Profit Growth of -121.00%.
What is the institutional holding pattern in ORCHPHARMA?
ORCHPHARMA has FII holding of 1.56% and DII holding of 19.04%. Significant institutional holding often suggests professional confidence in the Orchid Pharma Ltd stock.